7.9 Agents Affecting Histamine & Gastric Acid — Comprehensive Medicinal Chemistry Notes

Exam & Course Logistics

Handout packet: “Handouts” = student copy of slide deck; some slides withheld to keep focus on testable material.
Supplemental uploads (to download & archive):
• Extra slides (full-screen printing recommended)
• Specific learning objectives (most students ignore → those who read score higher)
• Structure set for every molecule shown in lecture (MANDATORY drawing practice)
• 1-page pH/ $pK_a$ review sheet + E/Z problem set
Drawing structures = single most effective Med-Chem study technique.
Exam 3 (Monday): 5 Q’s, all from today’s lecture.
• Dr Essel’s Thursday “Agents that affect the GI System” = on Exam 3.
• Friday lecture (PPIs) = only on Final.
Expect ≥1 pH/ $pK_a$ question per lecture set; also pro-/soft-drug recognition.
Program is accelerated → memorize structures now to save time later.
Philosophical note: Chemistry knowledge keeps pharmacy profession alive; losing it makes pharmacists replaceable middlemen.

Histamine Biology Refresher

Biosynthesis: Histidine −CO₂ → Histamine (stored in granules of mast cells, neurons, etc.).
Tautomers: move C=N within imidazole ring; biological relevance to receptor binding.
Functional groups & $pKa$ : • Primary amine $pKa \approx 9.4$
• Imidazole N (basic) $pK_a \approx 5.8$
• Forms: unionized ↔ monocation ↔ dication.
Acid–base rule of nines example: pH 10.4 ( > both $pK_a$ ) → histamine mostly unionized.
Receptors (all GPCR, 7-TM, constitutively active):
• H₁ – allergic rhinitis; 40 % homology to M₁/M₂ muscarinic → anticholinergic side-effects.
• H₂ – gastric parietal cells (acid secretion).
• H₃ – CNS (covered elsewhere).
• H₄ – immune cells (minimal exam relevance).
Constitutive activity ⇒ classical “antagonists” are actually inverse agonists (decrease basal signaling below zero line).

Mast-Cell Degranulation Inhibitors

MOA: prevent release of histamine & other mediators (not receptor blockade).
MUST be given prior to allergen exposure; ineffective post-exposure.
Structures not test-focus; remember timing requirement.

H₁ Antihistamines – First Generation (sedating, inverse agonists)

General SAR:

Ar–X–(spacer, usually –CH₂–CH₂–)–NR₃⁺           (Ar = 2 aromatic rings)

Classes, key features & examples:

Ethylenediamines
• Ethylene chain + 2 amines.
• High potency, highest sedation.
• Ex: Pyrilamine, Tripelennamine.
Ethanolamine Ethers
• Replace one N with O (–O–CH₂–).
• Prototype diphenhydramine (Benadryl) – OTC sleep aid; strong anticholinergic.
• Ring-constrained amine (e.g., Doxylamine, Clemastine) ↓ sedation.
Alkylamines
• Spacer = simple alkyl/alkenyl (no heteroatom).
• Longer duration, less sedation (Chlorpheniramine, Brompheniramine).
• $E$ isomer more potent than $Z$ across double bond.
Piperazines
• Piperazine ring (two N, 1,4-positions).
• Extra actions: anti-vertigo (Meclizine, Cyclizine), motion-sickness (Dramamine).
• Hydroxyzine = parent of 2nd-gen cetirizine.
Tricyclics
• Fused three-ring nucleus (phenothiazine, dibenzoxepin, etc.).
• Added antiemetic & antipruritic utility (Promethazine, Cyproheptadine).

Common side effects: CNS depression (sedation, mental clouding), anticholinergic (dry mouth, blurred vision, urinary retention).

Stereochemistry Toolkit (Exam-Critical)

Rings to recognize:
• Piperidine = one N in cyclohexane.
• Piperazine = two N opposite in ring.
CIP rules for $E/Z$ : compare priorities on EACH carbon of double bond; hydrogen lowest, lone pair even lower.
• Same side → $Z$ ("zusammen"); opposite → $E$ ("entgegen").
Nitrogen generally not a stereocenter due to rapid inversion; sulfur in sulfoxides CAN be stereogenic (see PPIs).

H₁ Antihistamines – Second Generation (non-/low-sedating)

Goals: maintain H₁ blockade, minimize CNS penetration & HERG liability.
Key trend: add polar carboxylic acid → zwitterion at physiologic pH, ↓ BBB entry.

Drug Pairs & Developmental Stories

Terfenadine → metabolite Fexofenadine (Allegra)
• Parent blocked HERG → fatal arrhythmias → withdrawn.
• Acid metabolite safe, marketed directly.
Astemizole similarly withdrawn (no safe acid derivative).
Loratadine (Claritin) → Carbamate hydrolysis → Desloratadine (Clarinex)
• Marketing ploy: pulled Rx Claritin 6 mo pre-patent-expiry to block generics; re-launched OTC while pushing Rx Clarinex.
Hydroxyzine → oxidized to Cetirizine (Zyrtec)
• Piperazine core retained, COOH added, minimal sedation.
Bilastine & others: designed de novo with COOH for non-sedating profile.

Hallmarks

Inverse agonists (like 1st-gen).
Presence of COOH usually = 2nd-gen; exceptions: Loratadine/Desloratadine (carbamate strategy).
Reduced CNS entry, limited anticholinergic burden.

Topical/Local H₁ Agents (FYI)

Olopatadine, Ketotifen, Azelastine eye drops/nasal sprays for allergic conjunctivitis/rhinitis.

H₂ Receptor Antagonists (Inverse Agonists)

Therapeutic use: ↓ gastric acid (GERD, PUD, adjunct in $H. pylori$ eradication).
General scaffold: substituted guanidine linked to lipophilic ring.

Prototype: Cimetidine—imidazole ring causes CYP450 inhibition & side-effects.
Successors: Ranitidine, Famotidine, Nizatidine, Roxatidine—remove imidazole, keep guanidine ( $pK_a≈14$ ) → fewer DDIs.
Safety note: Ranitidine recalled 2019 (NDMA nitrosamine impurity formed under heat/aging). Similar scrutiny for ARBs & metformin.

Proton Pump Inhibitors (PPIs)

Mechanism & Chemistry

Target: $H^+/K^+$ -ATPase (proton pump) on parietal cells; unrelated to histamine.
Prodrugs → acid-activated to sulfenamide electrophile → covalent bond (irreversible) with Cys-SH of pump.
Provide profound, long-lasting acid suppression; rebound hypersecretion on abrupt stop.
Acid-labile → formulated with enteric coating or sodium bicarbonate.

Key Molecules & Chirality

Omeprazole (Prilosec): racemate of $R$ and $S$ sulfoxides; metabolized mainly by CYP2C19 (genotype-dependent kinetics).
Esomeprazole = $S$ -enantiomer (prefix "eso-" from "S"); less inter-patient variability.
• Naming convention:
– "es-" / "lev-" / "dex-" etc. denote single enantiomer.
– Would be "r-" or "ar-" if $R$ isomer marketed.
Sulfoxide S center stereogenic because: four different substituents (one is the lone pair).
Non-chiral nitrogen within ring—rapid inversion unless locked in bicyclic system.

Clinical Pearls

PPIs > H₂ antagonists for potency but risk C-diff, fractures, B₁₂ deficiency with long-term use.
Genetic testing (CYP2C19) can optimize dose in poor vs ultra-rapid metabolizers.

Acid–Base & Compounding Relevance

$pK_a/pH$ mastery crucial for IV admixture questions ("Will drug precipitate in $\text{D5W}$ ?"; "Can I mix with bicarbonate?").
Rule of 9s: each 1-unit pH differential → 90 % shift in ionization for monoprotic acid/base; doubly applied for diprotics.

Study & Reference Resources

Practice E/Z & R/S with posted worksheet; exam likely includes stereochemistry ID.
Lemke’s “Review of Organic Functional Groups” (free via library) for rings, $pK_a$ tables, problem sets.
Keep personal digital/physical folder of landmark papers, structures, and review sheets for future practice.

Ethical & Professional Context

Drug companies exploit patent & regulatory loopholes (e.g., Claritin switch) → impacts formulary and patient cost.
Removal of ranitidine illustrates importance of post-marketing surveillance & impurity control.
Pharmacists as chemical experts remain vital in safeguarding safe medication use and advocating evidence-based choices.

Exam & Course Logistics

Handout packet: “Handouts” = student copy of slide deck; some slides are purposefully withheld to keep the focus on testable material and encourage active listening during lectures.
Supplemental uploads (to download & archive) are critical resources:
• Extra slides: These often contain additional visual aids or advanced concepts not explicitly covered in the main lecture, but which can deepen understanding. Full-screen printing is recommended for detailed study.
• Specific learning objectives: Crucially, most students ignore these, but those who thoroughly read and understand them consistently score higher on exams. These objectives directly guide the scope of exam questions.
• Structure set for every molecule shown in lecture: This document is MANDATORY drawing practice. Proficiency in drawing structures is fundamental for medicinal chemistry.
• 1-page pH/ $pK_a$ review sheet + E/Z problem set: These are essential for reviewing foundational chemical principles that will be applied to drug properties and interactions.
Drawing structures is the single most effective Med-Chem study technique, as it reinforces understanding of functional groups, stereochemistry, and drug interactions.
Exam 3 (Monday): Will consist of 5 questions, all derived exclusively from today’s lecture content.
• Dr. Essel’s Thursday lecture titled “Agents that affect the GI System” is also included on Exam 3.
• The Friday lecture on PPIs (Proton Pump Inhibitors) will only be on the Final Exam, not Exam 3.
Expect at least one pH/ $pK_a$ question per lecture set; also be prepared for pro-drug and soft-drug recognition and their implications for drug metabolism and action.
The program is accelerated, meaning the pace of content delivery is high. It is strongly advised to memorize drug structures now to prevent a backlog and save valuable study time later in the semester.
Philosophical note: A strong foundation in chemistry knowledge is what distinguishes and keeps the pharmacy profession vital and relevant. Without this understanding, pharmacists risk becoming replaceable middlemen in the healthcare system, simply dispensing rather than advising based on scientific principles.

Histamine Biology Refresher

Biosynthesis: Histamine is synthesized from the amino acid Histidine through a decarboxylation reaction (removal of $CO_2$ ). It is primarily stored in granules within mast cells, basophils, specific neurons in the CNS, and enterochromaffin-like cells (ECLs) in the stomach lining.
Tautomers: Tautomerism involves the reversible interconversion of constitutional isomers, specifically the movement of a proton and a double bond. In histamine, this refers to the shifting of the $C=N$ double bond within the imidazole ring. This tautomerism is of significant biological relevance as different tautomeric forms can interact differently with histamine receptors, influencing binding affinity and efficacy.
Functional groups & $pK_a$ : Understanding the ionization states of histamine is crucial for predicting its behavior at different pH levels and its interaction with biological targets.
• Primary amine ( $-CH2-CH2-NH2$ ) has a $pKa \approx 9.4$ . At physiological pH (7.4), this amine group will be predominantly protonated ( $NH_3^+$ ).
• Imidazole N (basic) has a $pK_a \approx 5.8$ . At physiological pH, the nitrogen within the imidazole ring will be mostly unprotonated (neutral).
• Forms: Depending on the pH, histamine can exist in various protonation states: a fully unionized form, a monocation (protonated primary amine), or a dication (both primary amine and imidazole nitrogen protonated).
Acid–base rule of nines example: This rule states that for every 1 unit of pH difference from the $pKa$ , the ratio of ionized to unionized form shifts by a factor of 10. For histamine, if the pH is 10.4 (which is 1 unit above the primary amine's $pKa$ of 9.4 and significantly above the imidazole's $pK_a$ of 5.8), histamine will be predominantly in its unionized form. This unionized form is generally more lipophilic and can thus more readily cross cell membranes.
Receptors (all GPCR, 7-TM, constitutively active): All four known histamine receptors (H₁, H₂, H₃, H₄) are G protein-coupled receptors (GPCRs) with seven transmembrane domains (7-TM). They exhibit constitutive activity, meaning they have a basal level of signaling even in the absence of a ligand.
• H₁ receptor: Primarily involved in allergic reactions (e.g., allergic rhinitis, urticaria) and mediating effects like vasodilation, increased vascular permeability, and itching. It has approximately 40% homology to M₁/M₂ muscarinic acetylcholine receptors, which explains why many first-generation H₁ antagonists exhibit significant anticholinergic side-effects (e.g., dry mouth, blurred vision, urinary retention).
• H₂ receptor: Located on gastric parietal cells and responsible for stimulating gastric acid secretion. Blocking this receptor reduces acid production.
• H₃ receptor: Primarily found in the CNS and involved in regulating neurotransmitter release (e.g., histamine, acetylcholine, serotonin, norepinephrine). Covered in more detail in CNS pharmacology lectures.
• H₄ receptor: Predominantly expressed on immune cells (e.g., mast cells, eosinophils, T cells) and involved in immune and inflammatory responses. It has minimal direct exam relevance for this course section.
Constitutive activity: Because histamine receptors are constitutively active, classical “antagonists” for these receptors are actually inverse agonists. Inverse agonists not only block the binding of the natural agonist but also reduce the receptor's basal signaling activity below its resting (unstimulated) level.

Mast-Cell Degranulation Inhibitors

MOA: These agents work by stabilizing mast cells, thereby preventing the release of histamine and other inflammatory mediators (e.g., leukotrienes, prostaglandins) from their granules. Their mechanism of action is not receptor blockade.
These drugs MUST be given prior to allergen exposure (prophylactically) to be effective; they are ineffective if administered after allergic symptoms have already begun, as the mediators have already been released.
Structures of these specific drugs are not a primary test-focus for this exam; however, remembering the crucial timing requirement for their clinical efficacy is essential.

H₁ Antihistamines – First Generation (sedating, inverse agonists)

General SAR (Structure-Activity Relationship):

Ar–X–(spacer, usually –CH₂–CH₂–)–NR₃⁺           (Ar = 2 aromatic rings)

This general structure indicates that a crucial pharmacophore for H₁ antihistamines involves two aromatic rings (Ar), connected via a linker (X, which can be C, O, or N) to a two-carbon spacer, which then attaches to a tertiary amine ( $NR3$ ) that is protonated at physiological pH ( $NR3^+$ ). The positive charge on the amine is critical for receptor binding.

Classes, key features & examples:
1. Ethylenediamines:
 • Characterized by an ethylene chain ( $-CH2-CH2-$ ) connecting two amine groups (one typically tertiary, the other part of the linker or a secondary amine linked to aromatic groups).
 • Known for high potency in blocking H₁ receptors and the highest degree of sedation among first-generation antihistamines.
 • Examples: Pyrilamine, Tripelennamine.
2. Ethanolamine Ethers:
 • In this class, one of the nitrogen atoms in the SAR is replaced by an oxygen atom, forming an ether linkage (e.g., $-O-CH2-CH2-NR_3^+$ ).
 • Prototype: Diphenhydramine (Benadryl) – widely available as an OTC sleep aid due to its strong sedative properties. It also exhibits potent anticholinergic activity, contributing to side effects like dry mouth, blurred vision, and urinary retention.
 • Ring-constrained amines within this class (e.g., Doxylamine, Clemastine) tend to reduce the flexibility of the molecule, which can sometimes lead to slightly less sedation compared to unconstrained analogs.
3. Alkylamines:
 • The spacer between the aromatic system and the amine is a simple alkyl or alkenyl chain (no heteroatom like O or N in the spacer itself).
 • Generally have a longer duration of action and comparatively less sedation than ethylenediamines or ethanolamine ethers, making them more suitable for daytime use.
 • Examples: Chlorpheniramine, Brompheniramine. These are often found in OTC cold preparations.
 • Stereochemistry note: For drugs like Chlorpheniramine, which have a double bond, the $E$ (entgegen) isomer is typically more potent than the $Z$ (zusammen) isomer regarding H₁ receptor affinity.
4. Piperazines:
 • Feature a piperazine ring, which is a six-membered ring containing two nitrogen atoms at 1,4-positions within its structure.
 • Beyond H₁ blockade, many piperazine derivatives possess additional pharmacological actions, such as anti-vertigo (e.g., Meclizine, Cyclizine) and motion-sickness prevention (e.g., Dimenhydrinate, marketed as Dramamine, which is a salt of diphenhydramine and 8-chlorotheophylline).
 • Hydroxyzine: This compound is notable as the parent molecule from which the second-generation H₁ antihistamine cetirizine is derived via oxidation.
5. Tricyclics:
 • Characterized by a fused three-ring nucleus, often derivatives of phenothiazine, dibenzoxepin, or similar heterocyclic systems.
 • These agents often display additional antiemetic (anti-nausea/vomiting) and antipruritic (anti-itching) utility due to their broader pharmacological profiles, often interacting with other receptor types.
 • Examples: Promethazine (a phenothiazine derivative with strong sedative and antiemetic effects), Cyproheptadine (a dibenzocycloheptene derivative with antihistaminic, antiserotonergic, and anticholinergic activities).
Common side effects: Due to their ability to cross the blood-brain barrier (BBB) and their promiscuous receptor binding profiles, first-generation H₁ antihistamines frequently cause CNS depression, manifesting as significant sedation, drowsiness, impaired cognitive function (

Histamine exists in different conformational states, particularly tautomeric forms due to the mobility of the $C=N$ double bond within its imidazole ring. This tautomerism is of significant biological relevance to receptor binding because different tautomeric forms can present slightly different electronic and steric profiles to a receptor's binding site. This can influence the binding

Histamine's imidazole ring exhibits two primary tautomeric forms: the Nτ-H tautomer and the Nπ-H tautomer. These forms differ in the position of the hydrogen atom on the imidazole nitrogen, leading to distinct electronic distributions and slight conformational variations, which are critical for their differential binding to histamine receptors.

Nτ-H Tautomer: In this form, the hydrogen is on the nitrogen atom furthest from the side chain (the 'tele' nitrogen, Nτ). This tautomer is often favored for binding to certain receptors due to its specific hydrogen bonding capabilities and steric presentation.
Nπ-H Tautomer: Here, the hydrogen is on the nitrogen atom closer to the side chain (the 'pros' nitrogen, Nπ). This form presents a different set of hydrogen bond donors/acceptors and a subtly different spatial arrangement, which may be more complementary to other receptor binding sites.

Differential Receptor Binding:

Each histamine receptor (H₁, H₂, H₃, H₄) has a unique binding pocket with specific amino acid residues arranged in a particular geometry. This leads to preferential interactions with one tautomeric form of histamine over another:

H₁ Receptors: These receptors often show a preference for the Nπ-H tautomer of histamine. The specific arrangement of residues in the H₁ binding site creates an environment where the Nπ-H form can optimally engage in hydrogen bonding and hydrophobic interactions, leading to effective binding and activation.
H₂ Receptors: In contrast, H₂ receptors typically prefer the Nτ-H tautomer. The H₂ receptor binding site is designed to accommodate and stabilize this specific tautomeric form, allowing for the precise orientation and interactions necessary for signal transduction that leads to gastric acid secretion.

This phenomenon highlights how the subtle chemical differences between tautomeric forms, driven by the dynamic movement of a proton within the molecule, are exploited by biological receptors to achieve specificity. The ability of a receptor to stabilize a particular tautomer through complementary interactions within its binding site dictates the binding affinity and the resulting physiological effect.

H₁ Antihistamines – First Generation (sedating, inverse agonists)

General SAR (Structure-Activity Relationship):

Ar–X–(spacer, usually –CH₂–CH₂–)–NR₃⁺           (Ar = 2 aromatic rings)

Classes, key features & examples related to activity and efficacy:
1. Ethylenediamines:
 • Characterized by an ethylene chain ( $-CH2-CH2-$ ) connecting two amine groups. The presence of two basic nitrogens influences their binding. High potency in blocking H₁ receptors and the highest degree of sedation among first-generation antihistamines, indicating significant CNS penetration and interaction with central H₁ receptors.
 • Ex: Pyrilamine, Tripelennamine.
2. Ethanolamine Ethers:
 • One nitrogen in the SAR is replaced by an oxygen atom, forming an ether linkage (e.g., $-O-CH2-CH2-NR_3^+$ ). The oxygen impacts lipophilicity and interactions. Prototype: Diphenhydramine (Benadryl) – strong sedative properties (high CNS penetration) and potent anticholinergic activity, which contributes to side effects but also some efficacy for motion sickness.
 • Ring-constrained amines (e.g., Doxylamine, Clemastine) reduce molecular flexibility, which can sometimes lead to slightly less sedation, suggesting a subtle impact on CNS entry or receptor interaction conformation.
3. Alkylamines:
 • The spacer is a simple alkyl or alkenyl chain (no heteroatom). This often results in a longer duration of action and comparatively less sedation, making them suitable for daytime use despite being first-generation.
 • Examples: Chlorpheniramine, Brompheniramine. These are commonly used due to their more favorable side-effect profile within the first-gen class.
 • Stereochemistry note: For drugs with a double bond, the $E$ (entgegen) isomer is typically more potent than the $Z$ (zusammen) isomer regarding H₁ receptor affinity, highlighting the importance of specific geometric conformation for optimal binding and activity.
4. Piperazines:
 • Feature a piperazine ring, a six-membered ring with two nitrogen atoms at 1,4-positions. The rigid ring structure and two nitrogens influence their pharmacodynamics. Beyond H₁ blockade, many piperazine derivatives exhibit additional pharmacological actions such as anti-vertigo (e.g., Meclizine, Cyclizine) and motion-sickness prevention (e.g., Dimenhydrinate), indicating broader activity beyond H₁ antagonism due to interactions with other receptor systems.
 • Hydroxyzine is a notable parent of the second-generation cetirizine.
5. Tricyclics:
 • Characterized by a fused three-ring nucleus (e.g., phenothiazine, dibenzoxepin). The bulky tricyclic system often allows for interaction with multiple receptor types. These agents often display added antiemetic and antipruritic utility, reflecting their broader pharmacological profiles and efficacy for symptoms beyond typical allergy, at the cost of increased side effects like prominent sedation.
 • Examples: Promethazine (strong sedative and antiemetic), Cyproheptadine.
Common side effects: CNS depression (sedation, mental clouding) and anticholinergic effects (dry mouth, blurred vision, urinary retention) are prevalent due to their ability to cross the blood-brain barrier (BBB) and promiscuous binding, especially to muscarinic receptors. These effects represent a trade-off in efficacy for desired H₁ blockade.

H₁ Antihistamines – Second Generation (non-/low-sedating)

Goals: Maintain potent H₁ blockade while minimizing CNS penetration and HERG cardiac channel liability.

Key SAR trend for improved safety and activity profile: The addition of a polar carboxylic acid group. This modification typically leads to the formation of a zwitterion at physiologic pH, which significantly reduces the drug’s ability to cross the BBB. This dramatically reduces sedative and anticholinergic side effects, improving patient adherence and safety profile.

Drug Pairs & Developmental Stories illustrating SAR improvements:

Terfenadine → metabolite Fexofenadine (Allegra):
• SAR Impact: Terfenadine, the parent drug, had a non-polar structure that allowed it to block HERG potassium channels, leading to fatal arrhythmias. However, its in vivo metabolism produced fexofenadine, which incorporates a carboxylic acid. Activity/Efficacy: This acid metabolite is safe and effective as an H₁ antihistamine, as its zwitterionic nature prevents significant CNS entry and HERG liability, making it non-sedating.
Astemizole similarly withdrawn (no safe acid derivative).
Loratadine (Claritin) → Carbamate hydrolysis → Desloratadine (Clarinex):
• SAR Impact: Loratadine, while less sedating than first-gen, is metabolically converted to desloratadine. Desloratadine retains the key features for H₁ antagonism but has specific structural nuances impacting its slightly different pharmacokinetic profile.
• Activity/Efficacy: Both are non-sedating H₁ inverse agonists. The development from one to the other was largely for marketing purposes rather than a significant safety or efficacy improvement over the parent.
Hydroxyzine → oxidized to Cetirizine (Zyrtec):
• SAR Impact: Hydroxyzine has a piperazine core and is more lipophilic and sedating. Oxidation introduces a carboxylic acid group, converting it to cetirizine. Activity/Efficacy: Cetirizine retains the piperazine core but the added COOH significantly reduces CNS penetration, resulting in minimal sedation. Its activity is maintained with a much improved side effect profile.
Bilastine & others: Designed de novo with COOH for non-sedating profile. This demonstrates a rational drug design approach based on SAR principles to achieve desired pharmacological activity without unwanted side effects.

Hallmarks of second-generation H₁ antihistamines related to activity and efficacy:

Inverse agonists (like 1st-gen): Their fundamental mechanism of H₁ receptor modulation (reducing basal activity) remains the same.
Presence of COOH usually = 2nd-gen: This acidic group is the primary SAR modification responsible for reduced CNS entry and thus reduced sedation and anticholinergic burden. Exceptions: Loratadine/Desloratadine use a carbamate strategy for improved CNS profile, which acts as a prodrug to a less polar active form, but overall still achieve non-sedating characteristics.
Reduced CNS entry, limited anticholinergic burden: These are direct consequences of the SAR modifications (especially the polar carboxylic acid), leading to a significantly improved safety and tolerability profile, allowing for broader clinical use where sedation would be problematic.

H₂ Receptor Antagonists (Inverse Agonists)

Activity and Efficacy: The primary therapeutic use of H₂ receptor antagonists is to reduce gastric acid secretion. This makes them highly effective in the treatment of conditions such as Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease (PUD), and as an adjunct therapy in the eradication of $H. pylori$ by reducing acid load, which aids antibiotic efficacy.

General Scaffold & SAR for Efficacy:

General Scaffold: These drugs are characterized by a substituted guanidine or similar basic group linked to a lipophilic ring system.
Prototype: Cimetidine
- Activity/Efficacy: Cimetidine was the pioneering H₂ antagonist. While effective in reducing gastric acid, its imidazole ring structure led to significant and problematic CYP450 inhibition. This non-selective CYP450 interaction meant it often caused numerous drug-drug interactions (DDIs), which limited its overall safety and efficacy profile in polypharmacy patients.
Successors: Ranitidine, Famotidine, Nizatidine, Roxatidine
- SAR Improvement & Efficacy: These newer agents were developed to overcome the DDI issues of Cimetidine. By removing the imidazole ring and incorporating different basic heterocycles (like the furan ring in Ranitidine, or thiazole ring in Famotidine) that retain the highly basic guanidine-like function (pK_a
  \approx 14), they maintain potent H₂ receptor blockade without significantly inhibiting CYP450 enzymes. This structural modification dramatically improved their safety profile by reducing DDIs, thereby increasing their practical efficacy and utility in broader patient populations.
- Safety Note: Despite their improved SAR for efficacy and safety, it's important to remember that Ranitidine was recalled due to the formation of NDMA (nitrosamine impurity) under certain conditions (heat/aging). This highlights the ongoing need for post-marketing surveillance even for established drugs, which affects their long-term efficacy and safety assessment.

Overall, H₂ receptor antagonists act as inverse agonists, effectively decreasing the basal signaling of the H₂ receptor below the zero line, leading to a profound and prolonged reduction in gastric acid secretion.

Activity and efficacy of H₁ antihistamines are directly tied to their Structure-Activity Relationship (SAR):

First-Generation H₁ Antihistamines (Sedating, Inverse Agonists)

General SAR: Characterized by two aromatic rings (Ar) linked via a heteroatom (X = C, O, or N) to a two-carbon spacer, terminating in a tertiary amine (-NR₃⁺) that is protonated at physiological pH. The positive charge on the amine is crucial for binding and activity.
Efficacy & Activity: All act as inverse agonists, reducing basal H₁ receptor activity. Their lipophilicity and smaller size allow them to readily cross the blood-brain barrier (BBB), leading to CNS effects. Their SAR also often allows for promiscuous binding to other receptors (e.g., muscarinic, adrenergic), contributing to their diverse side effects and additional uses. For example:
- Ethylenediamines: High potency and highest sedation due to optimal CNS penetration.
- Ethanolamine Ethers: Prototype Diphenhydramine (strong anticholinergic, sedative) due to structural features enhancing BBB crossing and muscarinic affinity.
- Alkylamines: Longer duration, less sedation (e.g., Chlorpheniramine) due to subtle SAR differences impacting CNS entry; $E$ isomer more potent than $Z$ due to specific geometric fit at the receptor.
- Piperazines: Piperazine ring confers anti-vertigo/motion-sickness efficacy in addition to H₁ blockade (e.g., Meclizine), reflecting broader receptor interactions.
- Tricyclics: Fused three-ring nucleus imparts antiemetic and antipruritic utility (e.g., Promethazine) due to bulkier structure allowing for interaction with multiple receptor types.

Second-Generation H₁ Antihistamines (Non-/Low-Sedating)

Goals: Maintain H₁ blockade with minimized CNS penetration and HERG cardiac channel liability.
Key SAR Trend for Efficacy & Safety: The strategic addition of a polar carboxylic acid group. This creates a zwitterion at physiological pH, significantly increasing hydrophilicity and largely preventing BBB entry.
SAR-Driven Efficacy & Safety: These drugs retain high H₁ receptor affinity (inverse agonism) but achieve a much safer profile. For instance:
- Fexofenadine (Allegra): A metabolite of Terfenadine, its carboxylic acid (SAR modification) eliminated HERG channel blockage while retaining H₁ efficacy, making it safe for direct marketing.
- Cetirizine (Zyrtec): Derived from Hydroxyzine via oxidation that introduces a carboxylic acid, it maintains H₁ potency but with minimal sedation due to reduced CNS penetration.
- Loratadine/Desloratadine: While not having a direct COOH, their carbamate SAR strategy still results in a non-sedating profile.

In essence, the precise arrangement of aromatic rings, spacers, and the nature of the basic amine, coupled with targeted modifications like adding polar groups, directly governs an H₁ antihistamine's potency, duration, CNS effects (sedation), and propensity for additional off-target activities or liabilities.

Proton Pump Inhibitors (PPIs)

Mechanism & Activity: PPIs are acid-activated prodrugs targeting the gastric $H^+/K^+$ -ATPase (proton pump) in parietal cells. Once activated in the acidic secretory canaliculi, they form an irreversible covalent bond with a cysteine residue on the pump.

Efficacy: This irreversible binding leads to profound and long-lasting cessation of gastric acid secretion, making them highly effective for conditions like GERD and PUD. Their efficacy is superior to H₂ antagonists due to this potent, sustained inhibition.

Key Aspects Affecting Efficacy/Safety:

Prodrug nature: Requires acid for activation, influencing formulation (enteric coating or co-administration with bicarbonate) to prevent degradation.
Chirality: Racemates (e.g., Omeprazole) or single enantiomers (e.g., Esomeprazole) may exhibit variable metabolism (e.g., via CYP2C19), which can impact individual efficacy.
Long-term use risks: While highly effective, prolonged use can lead to issues like increased C. difficile infection risk, fractures, and B₁₂ deficiency, influencing their long-term clinical utility and safety profile.

H₁ Antihistamines – First Generation (sedating, inverse agonists)

General SAR:

Ar–X–(spacer, usually –CH₂–CH₂–)–NR₃⁺ (Ar = 2 aromatic rings)

Drug Properties & Activity:
- Sedation: High. These drugs are generally lipophilic and possess a smaller molecular size, allowing them to readily cross the blood-brain barrier (BBB) and interact with H₁ receptors in the CNS, leading to significant CNS depression (sedation, mental clouding).
- Anticholinergic Effects: Prominent. Their SAR often leads to promiscuous binding to muscarinic acetylcholine receptors (e.g., M₁/M₂) due to structural homology, resulting in side effects like dry mouth, blurred vision, and urinary retention.
- Onset/Duration: Vary by class, but generally shorter duration compared to second-generation.
- Examples: Diphenhydramine, Chlorpheniramine, Promethazine.

H₁ Antihistamines – Second Generation (non-/low-sedating)

Goals: maintain H₁ blockade, minimize CNS penetration & HERG liability.

Key SAR Trend & Drug Properties:
- Added Polar Carboxylic Acid: This is the hallmark SAR modification. The introduction of a polar carboxylic acid group (COOH) creates a zwitterion at physiologic pH. This significantly increases the drug's hydrophilicity and molecular weight, which largely prevents it from crossing the BBB.
- Sedation: Minimal to none. Due to reduced CNS penetration, these drugs primarily act peripherally, avoiding central H₁ receptor blockade.
- Anticholinergic Effects: Limited. Their increased specificity and reduced CNS entry generally result in a much lower incidence of anticholinergic side effects.
- HERG Liability Reduced: Many second-generation drugs were developed to avoid the cardiac channel (HERG) blockade seen with withdrawn first-generation agents (e.g., Terfenadine), making them safer for cardiac patients.
- Onset/Duration: Generally longer-acting, allowing for once-daily dosing.
- Examples: Fexofenadine, Cetirizine, Loratadine.

Discrimination and Relation to Drug Properties

First-Generation vs. Second-Generation H₁ Antihistamines

The primary discrimination between first and second-generation H₁ antihistamines lies in their CNS penetration and associated side effect profiles, which are directly related to their Structure-Activity Relationship (SAR):

Sedation & CNS Effects:
- First-Generation: Characterized by lipophilic structures with smaller molecules that easily cross the blood-brain barrier (BBB). This allows them to block central H₁ receptors, leading to significant sedation and other CNS effects like cognitive impairment. Their general SAR (two aromatic rings, a spacer, and a protonated tertiary amine) contributes to this BBB permeability.
- Second-Generation: Designed with polar groups, most notably a carboxylic acid (COOH), which forms a zwitterion at physiological pH. This structural modification makes them highly hydrophilic and generally larger, hindering their ability to cross the BBB. Consequently, they exhibit minimal to no sedation as their action is primarily peripheral.
Anticholinergic Side Effects:
- First-Generation: Frequently possess significant anticholinergic activity (e.g., dry mouth, blurred vision, urinary retention) due to their structural promiscuity, allowing them to bind to muscarinic receptors (which share some homology with H₁ receptors).
- Second-Generation: Generally lack significant anticholinergic activity due to their increased receptor specificity and reduced ability to enter the CNS where these off-target effects are more pronounced.
Cardiac Safety (HERG Channel Liability):
- While not universally present, some first-generation agents (and early second-generation like Terfenadine and Astemizole, now withdrawn) showed HERG potassium channel blockade due to specific SAR features, leading to cardiac arrhythmias. This was a critical safety concern.
- Second-generation drugs were specifically developed to eliminate or significantly reduce this HERG liability through altered SAR, making them much safer, particularly for patients with cardiac conditions. For example, Fexofenadine is a safe metabolite of the withdrawn Terfenadine, due to the addition of a carboxylic acid.

The primary endogenous compound discussed is Histamine, a biogenic amine synthesized from Histidine. Its structure and ionization states are crucial for its diverse functions.

Structure and Functional Groups: Histamine contains a primary amine ( $-CH2-CH2-NH_2$ ) and an imidazole ring.
- The primary amine has a $pKa \approx 9.4$ . At physiological pH (7.4), it is predominantly protonated ( $NH3^+$ ). This positively charged group is essential for binding to histamine receptors.
- The imidazole N (basic) has a $pK_a \approx 5.8$ . At physiological pH, this nitrogen is mostly unprotonated (neutral).
- These functional groups allow histamine to exist in unionized, monocation, or dication forms depending on the pH, influencing its ability to cross membranes and interact with targets.
Tautomers and Receptor Affinity: The imidazole ring of histamine exhibits tautomerism, meaning the $C=N$ double bond can shift, leading to two main forms: Nτ-H and Nπ-H.
- These structural variations are fundamental to how histamine binds to its receptors.
- H₁ Receptors often show a preference for the Nπ-H tautomer, allowing for optimal hydrogen bonding and steric fit to mediate allergic responses (e.g., vasodilation, itching).
- H₂ Receptors typically prefer the Nτ-H tautomer, which is crucial for its precise orientation and interaction within the H₂ binding site to stimulate gastric acid secretion.

This structural flexibility and differential tautomer preference allow histamine to exert specific

The ionization state of a drug, whether it is protonated (ionized) or unprotonated (unionized), is determined by its inherent acidity or basicity (represented by its dissociation constant, $pK_a$ ) and the surrounding pH of the environment.

Definition of $pKa$ : The $pKa$ is the pH at which a drug is 50% ionized and 50% unionized.
General Rules:
- For an acidic drug: If the pH is below its $pKa$ , the drug will be predominantly unionized. If the pH is above its $pKa$ , it will be predominantly ionized.
- For a basic drug: If the pH is below its $pKa$ , the drug will be predominantly ionized. If the pH is above its $pKa$ , it will be predominantly unionized.
Rule of Nines: This rule provides a quick estimate of the degree of ionization for every 1-unit pH difference from the drug's $pKa$ . For a monoprotic acid or base, each 1-unit pH differential from the $pKa$ results in approximately a 90% shift towards one form. For example:
- If pH is 1 unit below a basic drug's $pK_a$ , it will be roughly 90% ionized.
- If pH is 1 unit above a basic drug's $pK_a$ , it will be roughly 90% unionized.
Example (Histamine from notes): Histamine is a base with two relevant $pKa$ values (primary amine $pKa ext{ } au 9.4$ , imidazole N $pKa ext{ } au 5.8$ ). If the pH is 10.4 (which is 1 unit above the primary amine's $pKa$ and significantly above the imidazole's $pK_a$ ), histamine will be mostly in its unionized form. This has significant implications for how well a drug can cross cell membranes, as unionized forms are generally more lipophilic.